Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) has a poor prognosis when treated with conventional chemotherapy. We analyzed the outcome of 67 HLA-identical sibling bone marrow transplants (BMTs) for Ph1-positive ALL reported to the International Bone Marrow Transplant Registry (IBMTR). Twenty-one of 67 (31%) transplant recipients survived in continuous complete remission more than 2 years after transplant. Two-year actuarial probabilities (95% confidence interval) of leukemia-free survival were 38% (23% to 55%) for 33 patients transplanted in first remission, 41% (23% to 61%) for 22 patients transplanted after relapse, and 25% (9% to 53%) for 12 patients failing to achieve remission with conventional chemotherapy. These data indicate that transplants are effective treatment for Ph1-positive ALL.
Barrett
A J
AJ
Department of Medicine, Medical College of Wisconsin, Milwaukee 53226.
Horowitz
M M
MM
Ash
R C
RC
Atkinson
K
K
Gale
R P
RP
Goldman
J M
JM
Henslee-Downey
P J
PJ
Herzig
R H
RH
Speck
B
B
Zwaan
F E
FE
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D006086:Graft vs Host Disease; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000601:surgery*; D012074:Remission Induction